This week's biggest % winners & losers : Dec. 13 - 17, 2021 (wk 50)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: ARNA (91.24 +82.7%), TRHC (15.59 +47.08%), NVAX (213.88 +28.41%), BHVN (122.89 +23.22%), PBYI (3.51 +23.16%), CERN (90.51 +21.7%), OPK (4.64 +19.98%), QDEL (160.49 +19.71%), ICPT (17.12 +19.22%), EGRX (54.38 +18.68%), ANAB (35.23 +17.43%), IRTC (105.24 +16.84%), KURA (14.21 +16.28%), FATE (56.81 +15.55%), ACAD (25.7 +15.45%), EPZM (3.17 +14.26%), VAPO (23.5 +14.19%), BLUE (10.23 +14.17%), ALLK (82.93 +13.91%)
• Information Technology: CCMP (187.31 +25.77%)

This week's top % losers

• Healthcare: QURE (20.62 -27.01%), MESO (4.72 -23.38%), BEAT (2.95 -22.7%), ENDP (3.7 -20.88%)
• Industrials: RUN (33.74 -20.24%), REVG (13.43 -18.21%)
• Consumer Discretionary: CPS (19.07 -26.57%), LOVE (64.34 -20.87%), CVNA (220.76 -18.48%), MOGU (0.43 -18.1%), BKE (41.46 -17.93%), TAL (4.19 -17.13%)
• Information Technology: HOLI (12.14 -18.3%)
• Financials: FANH (8.58 -19.96%), LC (23.55 -19.49%)
• Energy: SWN (4.5 -18.18%), NINE (1.06 -17.19%), CPG (4.4 -16.92%)

Long trade : CERN +17% (12/21)

• Dec. 13: #4; vol. 4.27M 

Cerner (CERN) to be acquired by Oracle (ORCL)?

Update Mon 12/20/21:  Oracle confirms plan to acquire Cerner through an all-cash tender offer for $95.00 per share, or approx. $28.3 bln in equity value.

***

 

 

Oracle (ORCL) is in talks to acquire medical records company Cerner (CERN) for about $30 billion, its largest acquisition ever and moving the enterprise software giant deeper into the health care sector. Oracle stock fell while Cerner shares soared.

The deal could be finalized soon, the Wall Street Journal reported, based on people familiar with the matter.

Oracle stock, which hit a record high last week, dropped 6.4%, closing at 96.62 on the stock market today. Cerner shares shot up 12.9%, closing at  89.77.

Cerner designs software that hospitals and doctors use to store and analyze medical records and other health care data. The chief executive of Cerner is David Feinberg, who was formerly vice president of Google Health. He joined Cerner Oct. 1.

Based in Kansas City, Mo., Cerner reported third-quarter revenue of $1.47 billion, up 7% from the year-ago period. Adjusted earnings climbed 19% to 86 cents a share. It has about 23,000 employees.

Cerner is the second largest seller of electronic health record software, after Epic Systems. Other competitors include Allscripts Healthcare Solutions (MDRX). Allscripts stock jumped 5.2%, closing at 18.54.

 

** CERN before **

 

Cerner (CERN) reported earnings on Thur 26 Oct 2017 (a/h)

** charts after earnings **

 

Cerner misses by $0.01, misses on revs; guides Q4 EPS, revs below consensus; guides FY18 EPS below consensus, revs in-line 

• Reports Q3 (Sep) earnings of $0.61 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.62; revenues rose 7.7% year/year to $1.28 bln vs the $1.29 bln Capital IQ Consensus.
• Co issues downside guidance for Q4, sees EPS of $0.60-0.62, excluding non-recurring items, vs. $0.68 Capital IQ Consensus Estimate; sees Q4 revs of $1.3-1.35 bln vs. $1.36 bln Capital IQ Consensus Estimate.
• Co issues guidancefor FY18, sees EPS of $2.52-2.68, excluding non-recurring items, vs. $2.78 Capital IQ Consensus Estimate; sees FY18 revs of $5.5-5.7 bln vs. $5.64 bln Capital IQ Consensus Estimate.
  • According to the company, these comments should be viewed as preliminary until the Company finalizes its financial plan and provides formal guidance when it reports fourth quarter results.

Long trade : CERN (9/17)

a.  8/14:  v.1.3 M   $63
b.  8/22:  +65    →   +3%

c.  8/29:  vol. 1.4M  $65
d.  9/7  vol. 3.4M   $69  →  +6%

  

Cerner (CERN)

In late April, leading supplier of health care information technology, Cerner (NASDAQ:CERN), broke higher on a continuation gap from a powerful bull channel that began in November 2010. We have recommended it many times before and had success each time. On Oct. 21, 2011, at about $66, we said it was a buy with a target of $75, and then on May 21, 2012, it was recommended on a pullback to $75, and it ran to over $88.

The company has exceeded its guidance in 9 of the past 10 quarters, and it again exceeded estimates in Q1, causing a revision of the full year 2013 estimate to $2.80 (up $0.10), and $3.29 in 2014.

CERN is a volatile stock, but that can be used to your advantage. A general market correction or slight earnings miss could cause the stock to fall to under $93, where traders should buy it for a trading target of at least $110. The longer-term objective is $120.